Page last updated: 2024-11-13
chondramide c
Description
chondramide C: a cytostatic cyclodepsipeptide; isolated from Chondromyces crocatus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
chondramide C : A chondramide formally obtained from N-[(2S,4E,6R,7R)-7-hydroxy-2,4,6-trimethyloct-4-enoyl]-L-alanyl-Nalpha-methyl-D-tryptophanyl-beta-R-beta-tyrosine by intramolecular condensation of the alcoholic hydroxy group with the carboxy group of the beta-tyrosine residue. It is produced by strains of the myxobacterium, Chondromyces crocatus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (7)
Synonym |
CHEMBL2426321 , |
chebi:84382 , |
(4r,7r,10s,13s,15e,17r,18r)-4-(4-hydroxyphenyl)-7-(1h-indol-3-ylmethyl)-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone |
chondramide c |
SCHEMBL15752251 , |
Q27157724 |
bdbm65516 |
Roles (2)
Role | Description |
bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
chondramide | Any of the 18-membered ring cyclodepsipeptides produced by strains of the myxobacterium, Chondromyces crocatus. |
indoles | Any compound containing an indole skeleton. |
phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
Actin | Saccharomyces cerevisiae S288C | IC50 (µMol) | 13.9000 | 0.0400 | 0.1683 | 0.3800 | AID1794862 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (3)
Assay ID | Title | Year | Journal | Article |
AID771592 | Antiparasitic activity against Toxoplasma gondii expressing beta-galactosidase infected in HFF assessed as parasite growth inhibition after 72 hrs | 2013 | Journal of natural products, Sep-27, Volume: 76, Issue:9
| Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii. |
AID771591 | Cytotoxicity against HFF after 72 hrs | 2013 | Journal of natural products, Sep-27, Volume: 76, Issue:9
| Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii. |
AID1794862 | Liquid growth assay from Article 10.1021/acschembio.7b00385: \\Direct Interaction of Chivosazole F with Actin Elicits Cell Responses Similar to Latrunculin A but Distinct from Chondramide.\\ | 2017 | ACS chemical biology, 09-15, Volume: 12, Issue:9
| Direct Interaction of Chivosazole F with Actin Elicits Cell Responses Similar to Latrunculin A but Distinct from Chondramide. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.25 (24.57) | Research Supply Index | 2.40 (2.92) | Research Growth Index | 4.65 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |